CAT-192 APPEARS TOLERABLE

Cambridge Antibody Technology and Genzyme Corp. announced preliminary results from a Phase I/II clinical trial of CAT-192, a human anti-TGF(Beta)1 monoclonal antibody. The primary objective of the trial was to assess the safety, tolerability, and pharmacokinetics of CAT-192 in patients suffering from diffuse systemic sclerosis.

Related Videos
Related Content

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023

Q1 Accepted NDAs and sBLAs to Keep a Watchful Eye On

March 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Frontline Forum Part 4: A Discussion of the Pathophysiology of Acne and Available Treatment Strategies

March 30th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Dupilumab Safe and Effective in Moderate-to-Severe Atopic Dermatitis

March 30th 2023

Silybum Marianum Fruit Extract Safe, Effective in Acne-Prone Skin

March 29th 2023
© 2023 MJH Life Sciences

All rights reserved.